索尔辛在癌症发展和化疗药物耐药性中的作用
Cécile Exertier1, Lorenzo Antonelli2, Annarita Fiorillo2
1Institute of Molecular Biology and Pathology, Italian National Research Council (IBPM-CNR), c/o Department Biochemical Sciences, Sapienza University of Rome, Ed. CU027, P.le A.Moro 5, 00185 Rome, Italy.
与可溶性耐药性相关的结合蛋白 (sorcin) 是一种驱动癌症多药性耐药性 (MDR) 的蛋白. 向sorcin可能会克服MDR并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 与可溶性耐药性相关的结合蛋白 (sorcin) 最初是由于其在多药耐药细胞中与ABCB1共同增强而被确定的.
- 新出现的证据突出显示了索尔辛作为一种瘤蛋白的活性作用,显著促进了多药性耐药性 (MDR).
- 素是一种结合蛋白,在人类瘤和多药耐药癌症中经常过度表达,作为潜在的MDR生物标志物.
研究的目的:
- 为了审查sorcin. 的结构和功能.
- 阐明素在癌症发展和多药耐药性方面的多方面的作用.
- 讨论针对sorcin克服药物耐药性的治疗策略.
主要方法:
- 对调查sorcin表达,功能和治疗向的研究进行文献综述.
- 分析数据,将素水平与患者对化疗反应和预后相关联.
- 检查来自细胞系和癌症模型的实验证据,以了解素对药物耐药性的影响.
主要成果:
- 索尔水平与患者对化疗的反应和瘤的整体预后相反相关.
- 多药耐药细胞系表现出明显更高的sorcin表达比他们的父母对手.
- 素的过度表达增强了化学抵抗,而其沉默则逆转了各种癌症类型的耐药性.
结论:
- 索尔辛通过多种机制积极促进多药性耐药性,包括药物排放,细胞死亡抑制和促进癌症进展.
- 索尔辛在瘤中的过度表达表明其作为潜在的治疗点的作用,以重新使癌细胞对化疗敏感.
- 向索尔是一种有希望的策略,可以对抗多种药物耐药性,并提高癌症治疗效率.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
09:58Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Inhibition of Cdk Activity
